Access the full text.
Sign up today, get DeepDyve free for 14 days.
Chien-Yi Yang, Chi-Hua Chen, Shin‐Tarng Deng, Chi‐Shan Huang, Yu‐Jr Lin, Yi-Ju Chen, Chun-Ying Wu, S. Hung, W. Chung (2015)
Allopurinol Use and Risk of Fatal Hypersensitivity Reactions: A Nationwide Population-Based Study in Taiwan.JAMA internal medicine, 175 9
(2015)
Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort studyThe BMJ, 351
M. Thurston, B. Phillips, Catherine Bourg (2013)
Safety and Efficacy of Allopurinol in Chronic Kidney DiseaseAnnals of Pharmacotherapy, 47
D. Picard, B. Janela, V. Descamps, M. D’Incan, P. Courville, S. Jacquot, S. Rogez, L. Mardivirin, H. Moins-Teisserenc, A. Toubert, J. Benichou, P. Joly, P. Musette (2010)
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A Multiorgan Antiviral T Cell ResponseScience Translational Medicine, 2
L. Sommers, R. Schoene (2002)
Allopurinol hypersensitivity syndrome associated with pancreatic exocrine abnormalities and new-onset diabetes mellitus.Archives of internal medicine, 162 10
J. Scott, A. Hall, R. Grahame (1966)
Allopurinol in treatment of gout.British Medical Journal, 2
T. Mikuls, J. Farrar, W. Bilker, S. Fernandes, H. Schumacher, K. Saag (2005)
Gout epidemiology: results from the UK General Practice Research Database, 1990–1999Annals of the Rheumatic Diseases, 64
H. Sumino, S. Ichikawa, T. Kanda, Tetsuya Nakamura, T. Sakamaki (1999)
Reduction of serum uric acid by hormone replacement therapy in postmenopausal women with hyperuricaemiaThe Lancet, 354
K. Hande, R. Noone, W. Stone (1984)
Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.The American journal of medicine, 76 1
L. Stamp, J. O’Donnell, Mei Zhang, J. James, C. Frampton, M. Barclay, P. Chapman (2011)
Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.Arthritis and rheumatism, 63 2
S. Beard, B. Scheele, G. Nuki, I. Pearson (2013)
Cost-effectiveness of febuxostat in chronic goutThe European Journal of Health Economics, 15
Chuang-Wei Wang, W. Chung, Yi-fang Cheng, N. Ying, K. Peck, Yuan-Tsong Chen, S. Hung (2013)
A new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders.The Journal of allergy and clinical immunology, 132 3
Hye‐Ryun Kang, Y. Jee, Yon-Soo Kim, Chang-Hwa Lee, J. Jung, Sae-Hoon Kim, Heung-Woo Park, Yoon-Seok Chang, I. Jang, Sang-Heon Cho, K. Min, Sang-Heon Kim, Kyung Lee (2011)
Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in KoreansPharmacogenetics and Genomics, 21
N. Kaniwa, Yoshiro Saito, M. Aihara, K. Matsunaga, M. Tohkin, K. Kurose, J. Sawada, H. Furuya, Yukitoshi Takahashi, M. Muramatsu, S. Kinoshita, Masamichi Abe, H. Ikeda, Mariko Kashiwagi, Yixuan Song, M. Ueta, C. Sotozono, Z. Ikezawa, R. Hasegawa (2008)
HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis.Pharmacogenomics, 9 11
S. Halevy, P. Ghislain, M. Mockenhaupt, J. Fagot, J. Bavinck, A. Sidoroff, L. Naldi, A. Dunant, C. Viboud, J. Roujeau (2008)
Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel.Journal of the American Academy of Dermatology, 58 1
L. Stamp, W. Taylor, Peter Jones, J. Dockerty, J. Drake, C. Frampton, N. Dalbeth (2012)
Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.Arthritis and rheumatism, 64 8
M. Caproni, D. Torchia, E. Schincaglia, W. Volpi, A. Frezzolini, D. Schena, A. Marzano, P. Quaglino, C. Simone, A. Parodi, E. Barletta, P. Fabbri (2006)
Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens–Johnson syndrome/toxic epidermal necrolysisBritish Journal of Dermatology, 155
A. Nassif, H. Moslehi, S. Gouvello, M. Bagot, L. Lyonnet, L. Michel, L. Boumsell, A. Bensussan, J. Roujeau (2004)
Evaluation of the potential role of cytokines in toxic epidermal necrolysis.The Journal of investigative dermatology, 123 5
The first study which identified HLA-B Ã 58 : 01 allele and its strong association with allopurinol-induced SCARs
S. Beard, B. Scheele, G. Nuki, I. Pearson (2014)
Erratum to: Cost-effectiveness of febuxostat in chronic goutThe European Journal of Health Economics, 15
Yanyan Zhu, Bhavik Pandya, Hyon Choi (2012)
Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008.The American journal of medicine, 125 7
Sheena Ramasamy, Cameron Korb-Wells, D. Kannangara, Myles Smith, nan wang, D. Roberts, G. Graham, K. Williams, R. Day (2013)
Allopurinol Hypersensitivity: A Systematic Review of All Published Cases, 1950–2012Drug Safety, 36
C. Lonjou, N. Borot, P. Sekula, N. Ledger, L. Thomas, S. Halevy, L. Naldi, J. Bouwes-Bavinck, A. Sidoroff, C. Toma, M. Schumacher, J. Roujeau, A. Hovnanian, M. Mockenhaupt (2008)
A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugsPharmacogenetics and Genomics, 18
W. Chung, R. Pan, Mu-Tzu Chu, See-Wen Chin, Yu-Lin Huang, Wei-Chi Wang, Jen-Yun Chang, S. Hung (2015)
Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse Reactions.The Journal of investigative dermatology, 135 9
G. Mcinnes, D. Lawson, H. Jick (1981)
Acute adverse reactions attributed to allopurinol in hospitalised patients.Annals of the Rheumatic Diseases, 40
A prospective cohort study from the United States suggested that the cumulative incidence of gout in middle age to age 65 was 8.6 and 2.5% in men and women
Rundles (1966)
Allopurinol in the treatment of goutAnn Intern Med, 64
B. Burke, A. Köttgen, Andrew Law, M. Grams, A. Baer, J. Coresh, M. McAdams‐DeMarco (2016)
Gout in Older Adults: The Atherosclerosis Risk in Communities Study.The journals of gerontology. Series A, Biological sciences and medical sciences, 71 4
A comorbid analysis showed a significantly increased risk of allopurinol hypersensitivity in asymptomatic hyperuricemia patients with underlying renal or cardiovascular diseases
Hui-yi Chou, C.‐B. Chen, C.‐Y. Cheng, Ya Chen, C. Ng, K. Kuo, W.‐L. Chen, Ch Chen (2015)
Febuxostat‐associated drug reaction with eosinophilia and systemic symptoms (DRESS)Journal of Clinical Pharmacy and Therapeutics, 40
C. Kuo, M. Grainge, C. Mallen, Weiya Zhang, M. Doherty (2014)
Rising burden of gout in the UK but continuing suboptimal management: a nationwide population studyAnnals of the Rheumatic Diseases, 74
This pathogenetic study demonstrated an important role of clonotype-specific T cells possessing preferential TCR and expressing granulysin upon oxypurinol induction
M. Fuldeore, A. Riedel, V. Zarotsky, Bhavik Pandya, O. Dabbous, E. Krishnan (2011)
Chronic kidney disease in gout in a managed care settingBMC Nephrology, 12
D. Winnard, C. Wright, W. Taylor, G. Jackson, Leanne Karu, P. Gow, B. Arroll, S. Thornley, B. Gribben, N. Dalbeth (2012)
National prevalence of gout derived from administrative health data in Aotearoa New Zealand.Rheumatology, 51 5
Ru Li, Jian Sun, L. Ren, Hong-yu Wang, Wen-Hong Liu, Xue-wu Zhang, Shi Chen, R. Mu, Jing He, Yi Zhao, L. Long, Yanying Liu, Xia Liu, Xiao-lan Lu, Yu-hui Li, Shi-yao Wang, Si-Si Pan, Chun Li, Hong-yuan Wang, Zhanguo Li (2012)
Epidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in Beijing.Rheumatology, 51 4
O. Lockard, C. Harmon, K. Nolph, W. Irvin (1976)
Allergic reaction to allopurinol with cross-reactivity to oxypurinol.Annals of internal medicine, 85 3
L. See, C. Kuo, Fang-Hsiu Chuang, Yu-ming Shen, Y. Ko, Yu-Ming Chen, Kuang-Hui Yu (2011)
Hyperuricemia and metabolic syndrome: associations with chronic kidney diseaseClinical Rheumatology, 30
W. Tassaneeyakul, T. Jantararoungtong, Pei Chen, Pao-Yu Lin, S. Tiamkao, Usanee Khunarkornsiri, P. Chucherd, Parinya Konyoung, S. Vannaprasaht, C. Choonhakarn, Pornrith Pisuttimarn, Alisara Sangviroon, W. Tassaneeyakul (2009)
Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai populationPharmacogenetics and Genomics, 19
S. Kardaun, P. Sekula, L. Valeyrie‐Allanore, Yvonne Liss, C. Chu, D. Creamer, A. Sidoroff, L. Naldi, M. Mockenhaupt, J. Roujeau (2013)
Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR studyBritish Journal of Dermatology, 169
Yanyan Zhu, Bhavik Pandya, Hyon Choi (2011)
Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008.Arthritis and rheumatism, 63 10
S. Hung, W. Chung, L. Liou, C. Chu, Marie Lin, H. Huang, Yen-Ling Lin, J. Lan, Li‐Cheng Yang, H. Hong, Ming-jing Chen, P. Lai, Mai-Szu Wu, C. Chu, Kuo‐Hsien Wang, Chien-Hsiun Chen, C. Fann, Jer-Yuarn Wu, Yuan-Tsong Chen (2005)
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.Proceedings of the National Academy of Sciences of the United States of America, 102 11
W. Chung, S. Hung, Jui-yung Yang, S. Su, Shien-Ping Huang, Chun-yu Wei, See-Wen Chin, C. Chiou, Sung‐Chao Chu, H. Ho, Chih‐hsun Yang, Chi Lu, Jer-Yuarn Wu, Y. Liao, Yuan-Tsong Chen (2008)
Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysisNature Medicine, 14
A. Riedel, M. Nelson, K. Wallace, N. Joseph‐Ridge, M. Cleary, A. Fam (2004)
Prevalence of Comorbid Conditions and Prescription Medication Use Among Patients With Gout and Hyperuricemia in a Managed Care SettingJCR: Journal of Clinical Rheumatology, 10
D. Khanna, J. Fitzgerald, P. Khanna, S. Bae, Manjit Singh, T. Neogi, M. Pillinger, Joan Merill, Susan Lee, Shraddha Prakash, Marian Kaldas, Maneesh Gogia, F. Pérez-Ruiz, W. Taylor, F. Lioté, Hyon Choi, J. Singh, N. Dalbeth, Sanford Kaplan, V. Niyyar, Danielle Jones, S. Yarows, B. Roessler, G. Kerr, Charles King, Gerald. Levy, D. Furst, N. Edwards, B. Mandell, H. Schumacher, Mark Robbins, N. Wenger, R. Terkeltaub (2012)
2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemiaArthritis Care & Research, 64
A. Dogan, M. Yarlıoglues, M. Kaya, Zakir Karadağ, S. Doğan, İdris Ardiç, O. Doğdu, Y. Kılınç, C. Zencir, M. Akpek, I. Ozdoğru, A. Oguzhan, N. Kalay (2011)
Effect of long-term and high-dose allopurinol therapy on endothelial function in normotensive diabetic patientsBlood Pressure, 20
Miao Hu, B. Tomlinson (2008)
Febuxostat in the management of hyperuricemia and chronic gout: a reviewTherapeutics and Clinical Risk Management, 4
A national prospective cohort study which showed that HLA-B Ã 58 : 01 screening prior to allopurinol prescription significantly lowered the incidence of allopurinolinduced SCARs in Taiwan
Yuqing Zhang, T. Neogi, Clara Chen, C. Chaisson, D. Hunter, Hyon Choi (2013)
Low-dose aspirin use and recurrent gout attacksAnnals of the Rheumatic Diseases, 73
The study showed a strong pharmacogenetic link between the HLA-B Ã 58 : 01 and allopurinol/oxypurinol, and the direct allopurinol binding site, Arg97, of the HLA-B Ã
C. Kuo, M. Grainge, L. See, Kuang-Hui Yu, S. Luo, A. Valdes, Weiya Zhang, M. Doherty (2013)
Familial aggregation of gout and relative genetic and environmental contributions: a nationwide population study in TaiwanAnnals of the Rheumatic Diseases, 74
Renal insufficiency and elevated plasma oxypurinol and granulysin were significantlly associated with poor prognosis in allopurinol-induced SCAR
I. Zineh, P. Mummaneni, J. Lyndly, Shashi Amur, L. Grenade, Stephen Chang, Hobart Rogers, M. Pacanowski (2011)
Allopurinol pharmacogenetics: assessment of potential clinical usefulness.Pharmacogenomics, 12 12
Joyce Singer, S. Wallace (1986)
The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality.Arthritis and rheumatism, 29 1
A recent epidemiologic study describing the prevalence and incidence of gout in the United Kingdom
S. Chohan (2011)
Safety and Efficacy of Febuxostat Treatment in Subjects with Gout and Severe Allopurinol Adverse ReactionsThe Journal of Rheumatology, 38
F. Málek, P. Ostadal, J. Parenica, Jirí Jarkovský, J. Vítovec, P. Widimsky, A. Linhart, M. Fedorco, Z. Coufal, R. Miklik, A. Krűger, D. Vondrakova, J. Špinar (2012)
Uric acid, allopurinol therapy, and mortality in patients with acute heart failure--results of the Acute HEart FAilure Database registry.Journal of critical care, 27 6
Emma Smith, C. Díaz-Torné, F. Pérez-Ruiz, Lyn March (2010)
Epidemiology of gout: an update.Best practice & research. Clinical rheumatology, 24 6
R. Keenan, W. O'Brien, Kristen Lee, D. Crittenden, M. Fisher, D. Goldfarb, S. Krasnokutsky, C. Oh, M. Pillinger (2011)
Prevalence of contraindications and prescription of pharmacologic therapies for gout.The American journal of medicine, 124 2
I. Gotsman, A. Keren, C. Lotan, D. Zwas (2012)
Changes in uric acid levels and allopurinol use in chronic heart failure: association with improved survival.Journal of cardiac failure, 18 9
Saskia Bruderer, M. Bodmer, S. Jick, C. Meier (2014)
Use of Diuretics and Risk of Incident Gout: A Population‐Based Case–Control StudyArthritis & Rheumatology, 66
A. Abeles (2012)
Febuxostat HypersensitivityThe Journal of Rheumatology, 39
A population-based study in Taiwan showed a higher risk of gout in people with a family history
Chia-Hsien Lin, Jung-Kuei Chen, T. Ko, Chun-yu Wei, Jer-Yuarn Wu, W. Chung, Shih-Yang Chen, Y. Liao, S. Hung, Yuan-Tsong Chen (2015)
Immunologic basis for allopurinol-induced severe cutaneous adverse reactions: HLA-B*58:01-restricted activation of drug-specific T cells and molecular interaction.The Journal of allergy and clinical immunology, 135 4
W. Chung, Wan-Chun Chang, S. Stocker, C. Juo, G. Graham, Ming-Han Lee, K. Williams, Ya-Chung Tian, Kuo-Chang Juan, Y. Wu, Chih‐hsun Yang, Chee-Jen Chang, Yu‐Jr Lin, R. Day, S. Hung (2014)
Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysinAnnals of the Rheumatic Diseases, 74
Derek Middleton, L. Menchaca, H. Rood, R. Komerofsky (2003)
New allele frequency database: http://www.allelefrequencies.net.Tissue antigens, 61 5
Purpose of review The article reviews the immunopathogenesis and risk factors related to allopurinol-induced severe cutaneous adverse reactions (SCARs). Recent findings For years, allopurinol remains one of the leading cause for SCARs worldwide. The pathogenesis of allopurinol-induced SCARs have been discovered in recent years. HLA-B ∗ 58 : 01 has been found to be strongly associated with allopurinol-SCARs with functional interactions between allopurinol/its metabolite-oxypurinol and the T-cell receptor (TCR). However, the genetic strength of HLA-B ∗ 58 : 01 may vary among different ethnic populations. In addition to HLA-B ∗ 58 : 01, specific T cells with preferential TCR clonotypes, which have no cross-reactivity with new xanthine oxidase inhibitors structurally different from allopurinol, are found to play a crucial role for allopurinol-induced SCARs. Furthermore, other nongenetic factors such as renal impairment are also found to be an important factor resulting in allopurinol-induced SCARs of greater severity and poorer prognosis. Summary There are multiple risk factors for allopurinol-induced SCARs, including genetic and nongenetic factors. Activation of specific T cells with preferential TCR and its functional interaction of HLA-B ∗ 58 : 01 molecule and allopurinol/oxypurinol are involved in the immune mechanism of allopurinol-induced SCAR. Patients with allopurinol-induced SCARs with renal impairment have significantly higher risk of mortality. A structurally different new generation xanthine oxidase inhibitor can provide a safer alternative for patients intolerant to allopurinol.
Current Opinion in Allergy and Clinical Immunology – Wolters Kluwer Health
Published: Aug 1, 2016
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.